Analyst
H.C. Wainwright
Equibles does not estimate personal net worth.
Yi Chen is recorded as Analyst at H.C. Wainwright. Yi Chen has spoken on 7 earnings calls across 6 companies, most recently for Bionano Genomics, Inc. on August 10, 2026. Those appearances were for Bionano Genomics, Inc. (BNGO), Biodesix Inc (BDSX), CareDx, Inc. (CDNA), LifeMD, Inc. (LFMD), Opko Health, Inc. (OPK) and 1 other company. The companies whose calls Yi Chen spoke on are classified in the Healthcare sector.
“You mentioned that you are raising the lower end of the revenue guidance for 2026. Could you tell us why the higher end is not raised as well?”
“So, with open expenses increasing just 7 percent, how are you balancing the accelerated commercial investment and also the pipeline development against the objective of sustained profitability?”
“So for the second quarter, you reported $16 million in prior period revenue. So can you talk about what are your expectations regarding prior period recognized revenue in the second half, particularly considering the final LCD will be effective on August the 30th.”
“Looking at the FDA's proposal to exclude semaglutides and that sort of drug from the bulk list, your shift to branded drugs kind of puts you ahead of that a little bit.”
“My first question is the reported first quarter revenue is just a little bit below your previous guidance. So can you talk about which segment in revenue sort of underperformed a little bit in the first quarter, and how should we look at the second quarter revenue guidance?”
H.C. Wainwright
Analyst
Source not stated
Medical Instruments & Supplies · Healthcare
BDSX
Diagnostics & Research · Healthcare
CDNA
Diagnostics & Research · Healthcare
LFMD
Health Information Services · Healthcare
RGNX
Biotechnology · Healthcare
